Hims & Hers Health Q2 Earnings Call Highlights
Hims & Hers Health reported Q2 adjusted gross margin of 64%, down about 6 points sequentially, and said margin pressure should continue in H2 as branded weight-loss and international revenue rise. The company rolled out AI for Hers weight-loss customers, citing 3x more messages and AI answering 80% of questions. Q3 revenue guidance is $880M to $900M; Q3 adj. EBITDA $75M to $95M.
How this was made
The 30-second read
Why it matters
Traders can use the disclosed Q3 and full-year 2026 adjusted EBITDA ranges, the 2H gross-margin pressure expectation, and the AI engagement and support-cost reduction metrics to reassess near-term profitability and growth quality.
Market read
Earnings call highlights include specific Q3 revenue and adjusted EBITDA guidance, continued 2H gross-margin pressure, and AI metrics (messages, AI answer rate, support task reduction) that may affect subscriber retention and cost-to-serve expectations.
What to watch
Legal overhang from FTC-related costs and working-capital drag tied to branded weight-loss expansion could weigh on near-term sentiment even if revenue growth is strong.
Background
The piece summarizes Hims & Hers’ Q2 earnings call, focusing on branded weight-loss retention, AI-enabled care rollout, margin outlook, and expansion into testosterone and peptides.
Ticker impact
Hims & Hers guided Q3 revenue to $880M-$900M and adjusted EBITDA to $75M-$95M after reporting Q2 adjusted gross margin at 64%.
Likely choppy reaction risk: upside from AI engagement metrics and international growth targets, offset by explicit 2H margin pressure and negative FCF.
The article contains concrete earnings and outlook numbers plus a clear margin headwind, which typically drives near-term repricing around guidance and profitability trajectory.
Market effects
Reinforces that DTC telehealth and weight-loss peers may face margin tradeoffs while scaling branded offerings and AI-enabled care workflows.
Highlights international expansion momentum (UK, Australia, Germany, Canada) that could influence investor focus on cross-border profitability paths.
Limited direct global macro linkage, but FDA-related peptide compounding validation underscores ongoing regulatory sensitivity for wellness/compounding categories.
Counterpoint
AI engagement gains may not translate into durable unit economics if gross-margin pressure persists and cancellations do not improve enough to offset higher branded and international mix.
Key entities
- companyHims & Hers Health, Inc.
Telehealth and direct-to-consumer personal care platform; reported Q2 results and provided Q3 and FY 2026 adjusted EBITDA outlook.
- regulatorFederal Trade Commission (FTC)
Referenced in connection with litigation costs and Hims & Hers’ intent to defend against an FTC complaint filed July 29.
- initiativeMenlo Park AI R&D lab
Planned AI research and development lab location tied to extending the AI-enabled care experience.
